• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Sera Prognostics Inc.

    3/19/25 4:19:27 PM ET
    $SERA
    Medical Specialities
    Health Care
    Get the next $SERA alert in real time by email
    S-8 1 sera-20250318.htm S-8 S-8

     

     

    Registration No. 333-

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

    Sera Prognostics, Inc.

    (Exact name of registrant as specified in its charter)

    Delaware

     

    26-1911522

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification Number)

    2749 East Parleys Way

    Suite 200
    Salt Lake City, UT 84109

    Telephone: (801) 990-0520

    (Address, including zip code, and telephone number, including area code,

    of registrant’s principal executive offices)

    2021 Equity Incentive Plan

    2021 Employee Stock Purchase Plan

    (Full Title of the Plans)

    Zhenya Lindgardt

    President and Chief Executive Officer

    Sera Prognostics, Inc.

    2749 East Parleys Way

    Suite 200

    Salt Lake City, UT 84109

    Telephone: (801) 990-0520

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer

    o

    Accelerated filer

    o

    Non-accelerated filer

    x

    Smaller reporting company

    x

     

     

    Emerging growth company

    x

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     


     

    EXPLANATORY NOTE

    This Registration Statement registers 1,328,276 additional shares of Class A Common Stock, par value $0.0001 per share (“Common Stock”), of Sera Prognostics, Inc. (the “Registrant”) under the Registrant’s 2021 Equity Incentive Plan (the “2021 Plan”) and 332,069 additional shares of Common Stock under the Registrant’s 2021 Employee Stock Purchase Plan (the “ESPP”), representing an increase of 1,328,276 shares of Common Stock reserved for issuance under the 2021 Plan and 332,069 shares of Common Stock reserved for issuance under the ESPP, in each case effective January 1, 2025 by operation of the “evergreen” provision contained in the applicable plan. This Registration Statement registers additional securities of the same class as other securities for which a registration statement filed on Form S-8 of the Registrant relating to one or more employee benefit plans is effective (File Nos. 333-258696, 333-263943, 333-270746, and 333-278104) (the “Prior Registration Statements”). The information contained in the Registrant’s Prior Registration Statements is hereby incorporated by reference pursuant to General Instruction E of Form S-8.

    2


     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 8. Exhibits

    Exhibit Number

     

    Exhibit Description

     

    Filed Herewith

     

    Incorporated by Reference herein from Form or Schedule

     

    Filing Date

     

    SEC File/Reg. Number

    4.1.1

     

    Amended and Restated Certificate of Incorporation

     

     

     

    Form 8-K (Exhibit 3.1)

     

    7/20/2021

     

    001-40606

    4.1.2

     

    Certificate of Amendment to Amended and Restated Certificate of Incorporation

     

     

     

    Form 8-K (Exhibit 3.1)

     

    6/9/2023

     

    001-40606

    4.2

     

    Amended and Restated Bylaws

     

     

     

    Form 8-K (Exhibit 3.2)

     

    7/20/2021

     

    001-40606

    4.3

     

    Specimen Common Stock Certificate

     

     

     

    Form S-1/A (Exhibit 4.1)

     

    7/8/2021

     

    333-257038

    4.4

     

    Form of Common Stock Purchase Warrant - I

     

     

     

    Form S-1 (Exhibit 4.2)

     

    6/11/2021

     

    333-257038

    4.5

     

    Form of Common Stock Purchase Warrant - II

     

     

     

    Form S-1 (Exhibit 4.3)

     

    6/11/2021

     

    333-257038

    4.6

     

    Form of Series E Warrant

     

     

     

    Form S-1 (Exhibit 4.4)

     

    6/11/2021

     

    333-257038

    4.7

     

    Fourth Amended and Restated Investors’ Rights Agreement, dated as of February 23, 2021

     

     

     

    Form S-1 (Exhibit 4.5)

     

    6/11/2021

     

    333-257038

    4.8

     

    Form of Pre-Funded Warrant

     

     

     

    Form 8-K (Exhibit 4.1)

     

    2/12/2025

     

    001-40606

    5.1

     

    Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

     

    X

     

     

     

     

     

     

    23.1

     

    Consent of Independent Registered Public Accounting Firm

     

    X

     

     

     

     

     

     

    23.2

     

    Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in Exhibit 5.1)

     

    X

     

     

     

     

     

     

    24.1

     

    Power of Attorney (included on the signature page hereof)

     

    X

     

     

     

     

     

     

    99.1+

     

    2021 Equity Incentive Plan

     

     

     

    Form S-1/A (Exhibit 10.3)

     

    7/8/2021

     

    333-257038

    99.2+

     

    Form of Stock Option Agreement under the Registrant’s 2021 Equity Incentive Plan

     

     

     

    Form S-1/A (Exhibit 10.3)

     

    7/8/2021

     

    333-257038

    99.3+

     

    Form of Restricted Stock Unit Agreement under the Registrant’s 2021 Equity Incentive Plan

     

     

     

    Form 10-K (Exhibit 10.29)

     

    3/20/2024

     

    001-40606

    99.4+

     

    2021 Employee Stock Purchase Plan

     

     

     

    Form S-1/A (Exhibit 10.4)

     

    7/8/2021

     

    333-257038

    107

     

    Filing Fee Table

     

    X

     

     

     

     

     

     

    __________________________________

    + Denotes management contract or compensatory plan or arrangement

    3


     

    Signatures

    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this registration statement on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized in Salt Lake City, Utah, on the 19th day of March, 2025.

    SERA PROGNOSTICS, INC.

    By: /s/ Zhenya Lindgardt

    Zhenya Lindgardt

    President and Chief Executive Officer

    POWER OF ATTORNEY

    Each person whose signature appears below constitutes and appoints each of Zhenya Lindgardt and Austin Aerts, acting alone or together with another attorney-in-fact, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for such person and in his or her name, place and stead, in any and all capacities, to sign any or all further amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

    Signature

     

    Title

     

    Date

     

     

     

     

     

    /s/ Zhenya Lindgardt

     

    President and Chief Executive Officer (Principal Executive Officer)

     

    March 19, 2025

    Zhenya Lindgardt

     

     

     

     

     

     

     

    /s/ Austin Aerts

     

    Chief Financial Officer (Principal Financial and Accounting Officer)

     

    March 19, 2025

    Austin Aerts

     

     

     

     

     

    /s/ Kim Kamdar, Ph.D.

     

    Chair of the Board of Directors

     

    March 19, 2025

    Kim Kamdar, Ph.D.

     

     

     

     

     

    /s/ Jane F. Barlow, M.D.

     

    Director

     

     

    March 19, 2025

    Jane F. Barlow, M.D.

     

     

     

     

     

    /s/ Gregory C. Critchfield, M.D., M.S.

     

    Director

     

     

    March 19, 2025

    Gregory C. Critchfield, M.D., M.S.

     

     

     

     

     

    /s/ Sandra A.J. Lawrence

     

    Director

     

     

    March 19, 2025

    Sandra A.J. Lawrence

     

     

     

     

     

    /s/ Mansoor Raza Mirza, M.D.

     

    Director

     

     

    March 19, 2025

    Mansoor Raza Mirza, M.D.

     

     

     

     

     

    /s/ Joshua Phillips

     

    Director

     

     

    March 19, 2025

    Joshua Phillips

     

     

     

     

     

     

     

    /s/ Ryan Trimble

     

    Director

     

     

    March 19, 2025

    Ryan Trimble

     

     

     

     

     

     

     

    /s/ Marcus Wilson, Pharm.D.

     

    Director

     

     

    March 19, 2025

    Marcus Wilson, Pharm.D.

     

     

     

    4


    Get the next $SERA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SERA

    DatePrice TargetRatingAnalyst
    12/15/2025$5.00Buy
    Jefferies
    3/30/2022$18.00 → $4.00Buy → Neutral
    Citigroup
    11/19/2021$19.00Outperform
    Oppenheimer
    10/15/2021Outperform
    Cowen
    8/9/2021Outperform
    William Blair
    8/9/2021Outperform
    Cowen
    8/9/2021$18.00Buy
    Citigroup
    More analyst ratings

    $SERA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kamdar Kim P. disposed of 30,920 shares and acquired 3,231 shares, increasing direct ownership by 11% to 32,573 units (SEC Form 4)

    4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

    2/4/26 5:03:47 PM ET
    $SERA
    Medical Specialities
    Health Care

    Chief Information Officer Harrison Robert Gardner sold $5,940 worth of shares (2,000 units at $2.97), decreasing direct ownership by 2% to 82,788 units (SEC Form 4)

    4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

    1/27/26 5:12:53 PM ET
    $SERA
    Medical Specialities
    Health Care

    Chief Information Officer Harrison Robert Gardner sold $6,000 worth of shares (2,000 units at $3.00), decreasing direct ownership by 2% to 84,788 units (SEC Form 4)

    4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

    12/30/25 6:41:19 PM ET
    $SERA
    Medical Specialities
    Health Care

    $SERA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Landmark Study Finds PreTRM® Blood Test Reduces Earliest Preterm Births and Newborn Complications

    Published in the journal PREGNANCY, the PRIME Study demonstrates significant improvements in neonatal outcomes with early risk screening and targeted interventions. SALT LAKE CITY, Jan. 7, 2026 /PRNewswire/ -- A randomized controlled trial of 5,018 women has found that a simple blood test, when paired with targeted interventions, can significantly reduce the risk of preterm birth and improve outcomes for newborns. The findings, published in PREGNANCY, the peer-reviewed journal of the Society for Maternal-Fetal Medicine, highlight the effectiveness of the PreTRM Test in identifying women at higher risk for spontaneous preterm birth and guiding preventive care.

    1/7/26 8:30:00 AM ET
    $SERA
    Medical Specialities
    Health Care

    Sera Announces Publication Acceptance for PRIME Study

    The PRIME study, one of the largest studies on preterm birth, has been accepted for publication by a medical journal following abstract presentation earlier this year SALT LAKE CITY, Nov. 24, 2025 /PRNewswire/ -- Sera Prognostics, Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the findings of the Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal OutcoMEs (PRIME) study were accepted for publication in a peer-reviewed  journal.

    11/24/25 8:00:00 AM ET
    $SERA
    Medical Specialities
    Health Care

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    $SERA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $SERA
    SEC Filings

    View All

    Jefferies initiated coverage on Sera Prognostics with a new price target

    Jefferies initiated coverage of Sera Prognostics with a rating of Buy and set a new price target of $5.00

    12/15/25 10:01:13 AM ET
    $SERA
    Medical Specialities
    Health Care

    Sera Prognostics downgraded by Citigroup with a new price target

    Citigroup downgraded Sera Prognostics from Buy to Neutral and set a new price target of $4.00 from $18.00 previously

    3/30/22 7:52:32 AM ET
    $SERA
    Medical Specialities
    Health Care

    Oppenheimer initiated coverage on Sera Prognostics with a new price target

    Oppenheimer initiated coverage of Sera Prognostics with a rating of Outperform and set a new price target of $19.00

    11/19/21 4:55:47 AM ET
    $SERA
    Medical Specialities
    Health Care

    SEC Form 144 filed by Sera Prognostics Inc.

    144 - SERA PROGNOSTICS, INC. (0001534969) (Subject)

    1/27/26 4:18:25 PM ET
    $SERA
    Medical Specialities
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Sera Prognostics Inc.

    SCHEDULE 13G/A - SERA PROGNOSTICS, INC. (0001534969) (Subject)

    1/16/26 2:45:31 PM ET
    $SERA
    Medical Specialities
    Health Care

    Sera Prognostics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - SERA PROGNOSTICS, INC. (0001534969) (Filer)

    1/8/26 5:20:58 PM ET
    $SERA
    Medical Specialities
    Health Care

    $SERA
    Financials

    Live finance-specific insights

    View All

    SERA PROGNOSTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

    SALT LAKE CITY, Nov. 13, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the third quarter of 2025 ended September 30, 2025. Third Quarter and Recent Highlights: Meaningful progress on payer initiatives, including an inaugural pilot in Nevada actively enrolling Medicaid patients, while engaging with multiple payers across thirteen states, collectively representing a significant

    11/13/25 4:05:00 PM ET
    $SERA
    Medical Specialities
    Health Care

    SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF THIRD QUARTER FISCAL YEAR 2025 FINANCIAL RESULTS ON NOVEMBER 13, 2025

    SALT LAKE CITY, Oct. 30, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced it will report third quarter fiscal year 2025 financial results on Thursday November 13, 2025, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.

    10/30/25 4:05:00 PM ET
    $SERA
    Medical Specialities
    Health Care

    SERA PROGNOSTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

    SALT LAKE CITY, Aug. 6, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the second quarter of 2025 ended June 30, 2025. Second Quarter and Recent Highlights: Ongoing progress in engaging Medicaid plans in targeted states with prior PreTRM clinical study experience. Notable traction in two particular states with above-average premature birth rates, presenting strong commercial o

    8/6/25 4:05:00 PM ET
    $SERA
    Medical Specialities
    Health Care

    $SERA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    $SERA
    Leadership Updates

    Live Leadership Updates

    View All

    Amendment: SEC Form SC 13G/A filed by Sera Prognostics Inc.

    SC 13G/A - SERA PROGNOSTICS, INC. (0001534969) (Subject)

    11/14/24 5:46:12 PM ET
    $SERA
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sera Prognostics Inc.

    SC 13G/A - SERA PROGNOSTICS, INC. (0001534969) (Subject)

    11/4/24 7:19:49 AM ET
    $SERA
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Sera Prognostics Inc.

    SC 13G - SERA PROGNOSTICS, INC. (0001534969) (Subject)

    4/1/24 7:33:43 PM ET
    $SERA
    Medical Specialities
    Health Care

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    Sera Prognostics Names Dr. Tiffany Inglis Chief Medical Officer

    SALT LAKE CITY, Oct. 1, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker testing to help deliver information to doctors and patients, today announced the appointment of Tiffany Inglis, MD, FACOG, as Chief Medical Officer. With extensive clinical leadership expertise, Dr. Inglis will lead Sera's clinical operations to establish the company as a leader in women's health diagnostics to improve the health of pregnant women and newborns. Dr. Inglis joins Se

    10/1/25 8:05:00 AM ET
    $SERA
    Medical Specialities
    Health Care

    SERA PROGNOSTICS APPOINTS LEE ANDERSON AS CHIEF COMMERCIAL OFFICER

    Industry Veteran to Spearhead Commercial Expansion, Driving Innovation and Growth at the Company SALT LAKE CITY, May 8, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the appointment of Lee Anderson as Chief Commercial Officer. Bringing more than 30 years of cross-functional leadership experience in sales, marketing, customer service, strategic accounts, and training, Mr. Anderson has a proven track record of driving business growth and enhancing sales strategies in the healthcare sector.

    5/8/25 4:40:00 PM ET
    $SERA
    Medical Specialities
    Health Care